India's PLI scheme sets stage for semaglutide production in 2026

30 June 2024

India's Production Linked Incentive (PLI) scheme has struck gold with the inclusion of semaglutide, a key GLP-1 receptor agonist used in the treatment of diabetes and obesity.

The Indian government has unveiled plans to incentivize the domestic production of these glucagon-like peptide receptor agonist (GLP-1) drugs. Beginning 2026, India will start manufacturing these popular peptide medications, specifically GLP-1 receptor agonists (GLP-1RAs), under the PLI scheme, reports The Pharma Letter’s India correspondent.

The patent for semaglutide, the active ingredient in Novo Nordisk's (NOV: N) popular drugs Wegovy (for obesity) and Ozempic (for diabetes), is set to expire in India by 2026. Indian companies are preparing to produce these medications under the government's PLI scheme, said a senior government official.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK